



MEDICAL POLICY STATEMENT OHIO MEDICAID

Original Issue Date	Next Annual Review	Effective Date	
06/01/2009	05/01/2019	05/01/2018	
Policy Name		Policy Number	
Mastectomy for Gynecomastia		MM-0002	
Policy Type			
MEDICAL	Administrative	Pharmacy	Reimbursement

Medical Policy Statements prepared by CSMG Co. and its affiliates (including CareSource) are derived from literature based on and supported by clinical guidelines, nationally recognized utilization and technology assessment guidelines, other medical management industry standards, and published MCO clinical policy guidelines. Medically necessary services include, but are not limited to, those health care services or supplies that are proper and necessary for the diagnosis or treatment of disease, illness, or injury and without which the patient can be expected to suffer prolonged, increased or new morbidity, impairment of function, dysfunction of a body organ or part, or significant pain and discomfort. These services meet the standards of good medical practice in the local area, are the lowest cost alternative, and are not provided mainly for the convenience of the member or provider. Medically necessary services also include those services defined in any Evidence of Coverage documents, Medical Policy Statements, Provider Manuals, Member Handbooks, and/or other policies and procedures.

Medical Policy Statements prepared by CSMG Co. and its affiliates (including CareSource) do not ensure an authorization or payment of services. Please refer to the plan contract (often referred to as the Evidence of Coverage) for the service(s) referenced in the Medical Policy Statement. If there is a conflict between the Medical Policy Statement and the plan contract (i.e., Evidence of Coverage), then the plan contract (i.e., Evidence of Coverage) will be the controlling document used to make the determination.

Contents of Policy

<u>MEDICAL POLICY STATEMENT</u>	1
<u>TABLE OF CONTENTS</u>	1
<u>A. SUBJECT</u>	2
<u>B. BACKGROUND</u>	2
<u>C. DEFINITIONS</u>	2
<u>D. POLICY</u>	2
<u>E. CONDITIONS OF COVERAGE</u>	3
<u>F. RELATED POLICIES/RULES</u>	3
<u>G. REVIEW/REVISION HISTORY</u>	3
<u>H. REFERENCES</u>	3



A. SUBJECT

Mastectomy for Gynecomastia

B. BACKGROUND

Gynecomastia is the benign proliferation, either unilateral or bilateral, of glandular tissue of the breast in males. This develops most often in the setting of altered estrogen/androgen balance or increased sensitivity of breast tissue to estrogen.

Causes may include among others) androgen deficiency states (e.g. treatments for prostate carcinoma), congenital disorders (e.g. Klinefelter's Syndrome (47XXY)), medications (estrogen replacement therapy, calcium channel blockers, cimetidine, phenothiazines, spironolactone, theophylline, HAART for HIV/AIDS), chronic medical conditions (e.g. cirrhosis, chronic kidney disease), tumors (e.g. adrenal or testicular) or endocrine disorders (e.g., hyperthyroidism).

As a result of this hormonal imbalance medical therapy may be offered in the treatment of gynecomastia (i.e. anti-estrogens, androgens, or aromatase inhibitors). Gynecomastia should not be confused with pseudo-gynecomastia which is usually transient and resolves in 6-24 months.

C. DEFINITIONS

- **Persistent pubertal gynecomastia:** The persistence of breast enlargement following the end of puberty and occasionally lasting into adulthood.
- **Pseudo-gynecomastia:** Enlargement of the breast due to fat deposition (without glandular involvement), typically occurring in the setting of obesity.
- **Pubertal gynecomastia:** A benign process occurring most commonly between the ages of 10 to 13 typically followed by regression in most cases.

D. POLICY

- I. *Mastectomy for Gynecomastia may be indicated by 1 or more of the following:*
 - A. *Postpubertal male and all of the following:*
 1. *Gynecomastia has been present for 12 months or greater*
 2. *Gynecomastia did not regress after cessation of medications (eg, calcium blockers, cimetidine, phenothiazines, spironolactone, theophylline) known to cause condition, or medications cannot be discontinued*
 3. *Mammography or needle biopsy results show no evidence of breast cancer*
 4. *No evidence of other medical causes for gynecomastia, as indicated by normal results for all of the following tests:*
 - 4.1 *Hormone evaluation (i.e. testosterone, luteinizing hormone, follicle-stimulating hormone, estradiol, prolactin, beta-human chorionic gonadotropin)*
 - 4.2 *Liver enzymes*
 - 4.3 *Serum creatinine*
 - 4.4 *Thyroid function tests*
 - 4.5 *Functional impairment is documented (i.e. chronic skin irritation, pain, paresthesias)*
 - B. *Pubertal male and all of the following:*
 1. *Functional impairment (i.e. chronic skin irritation, pain, paresthesias, related psychological disorder requiring therapy*
 2. *Gynecomastia present for 2 OR MORE years*
 3. *Preoperative photographs are provided*
 - C. *Mastectomy for Gynecomastia is considered not medically necessary under the*



following circumstances:

1. If the above listed criteria are not met.
 2. Breast enlargement resulting from obesity.
- D. **Liposuction:** to perform mastectomy for Gynecomastia is considered investigational and not medically necessary
- E. **Reconstructive Surgery:** Mastectomy for gynecomastia is considered reconstructive if it meets the following criteria:
1. Is performed on abnormal structures of the breast arising from congenital defects or the result of trauma or disease of the breast
 2. Is associated with physical-functional impairment which can be improved by the surgery

E. CONDITIONS OF COVERAGE

HCPCS
CPT

AUTHORIZATION PERIOD

F. RELATED POLICIES/RULES

N/A

G. REVIEW/REVISION HISTORY

DATES		ACTION
Date issued	06/01/2009	
Date Revised	06/01/2009, 07/01/2011, 11/01/2011, 02/01/2014, 02/11/2015, 02/01/2016	
	09/27/2017	Language change to include <i>Gynecomastia did not regress after cessation of medications (eg, calcium blockers, cimetidine, phenothiazines, spironolactone, theophylline; updated references.</i>
Date Effective	05/01/2018	

H. REFERENCES

1. AreaMJ, Caniano DA. Breast disorders in the adolescent patient. *Adolesc. Med Clin.* 2005; 15(3):473-485.
2. CakanN, Kamat D. Gynecomastia: evaluation and treatment recommendations for primary care providers. *Clin Pediatrics Phila.* 2007; 46(6):487-490.
3. McGrath MH, Schooler WG Elective plastic surgery procedure in adolescence. *Adolesc. Med Clinics* 2007; 15(3); 244-249.
4. Behrman et al Nelson's Textbook of Pediatrics, 18 Education 2007: 2385-87.
5. Neinstein LS et al Adolescent Health Care, 5th Education 2007: 210-214.
6. Pescowitz, O, Eugster, E *Pediatrics Endocrinoly:* 351-357.
7. Milliman MCG, 20th ED.
8. Braunstein G.D et al. UpToDate; Epidemiology, pathophysiology, and causes of gynecomastia. Updated 7/2/2014. Management of Gynecomastia, Updated 7/18/2014.
9. Li RZ, Xia Z, Lin HH, Wen Y, Wu J, Wang HW. Childhood gynecomastia: a clinical analysis of 240 cases. *Zhongguo Dang Dai er Ke Za Zhi* 2007;9(5):404-6.
10. Braunstein, G. D., Emeritus, Md. of M., & Geffen, D. Management of gynecomastia. Retrieved January 17, 2017, from <https://www.uptodate.com/contents/management-of->



[gynecomastia?source=search_result&search=liposuction%20for%20gynecomastia%20male&selectedTitle=1~150#H20245030](https://pubmed.ncbi.nlm.nih.gov/3080063/)

12. Qutob, O., Elahi, B., Garimella, V., Ihsan, N., & Drew, P. (2010). Minimally invasive excision of gynecomastia – a novel and effective surgical technique. , 92(3), . Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3080063/>

This guideline contains custom content that has been modified from the standard care guidelines and has not been reviewed or approved by MCG Health, LLC.

The Medical Policy Statement detailed above has received due consideration as defined in the Medical Policy Statement Policy and is approved.

Archived